Moroccan/Swedish record producer RedOne to perform in Bahrain

RedOne is a multitalented Moroccan/Swedish record producer behind over 70 international hit singles including 35 (and counting) #1 singles. (Supplied)
Updated 10 January 2019
0

Moroccan/Swedish record producer RedOne to perform in Bahrain

  • The meeting of RedOne and Lady Gaga was the beginning of a mutual worldwide success story
  • RedOne will appear in Bahrain as part of his 2019 Big World Tour — featuring special guests

RIYADH: RedOne, the top multi Grammy award-winning producer, singer, musician and songwriter is coming for a 2-day stay in Bahrain (10-12th January 2019). RedOne is a multitalented Moroccan/Swedish record producer and executive behind over 70 international hit singles including 35 (and counting) #1 singles, which has made him one of the most successful and sought after record producers and songwriters in the world.

If you are wondering what is the common denominator of Nicki Minaj, Lady Gaga, Jennifer Lopez, Rihanna, Usher, Marc Anthony, Quincy Jones, Enrique Iglesias, Nicole Scherzinger, Mary J Blige, Cheb Khaled, Mylene Farmer and One Direction? The answer is RedOne, who collaborated with all of these big stars and inspired them.

Two of the albums that he had produced had more than 700 million records sold with three record-breaking hits (Bad Romance, On The Floor, Poker Face). It takes discipline to prevail and that’s why RedOne works hard and demands perfection of himself to write a song for all the great artists that he works with. His passion for music and love for the people inspires him to write songs that later become worldwide hits.

RedOne is like a powerful magnet. Whenever he crosses paths with a talented singer, famous or not, he radiates a positive energy which transcends the person’s career to dizzying heights. He has proven to be an inspiration to the Music World for over two decades but has remained humble of the musical phenomena he has created from scratch.

Despite all of his successes, RedOne has kept his feet on the ground. He had to go through a difficult path when he started his career, struggling in Sweden and later in the USA, before reaching a remarkable success as he pursued his dreams of becoming a famous singer and songwriter.

The meeting of RedOne and Lady Gaga, when she was a raw prototype of herself, was definitely the start of a mutual worldwide success which lead to the inception of hits like “Poker Face”, “Alejandro” and the exemplary “Monster” track.

At this stage, RedOne is not only an artist but sees himself as a “Citizen of the World” and committed to his principle of spreading love to everyone through his published songs and his next featured album to be released in 2019.

RedOne will appear in Bahrain as part of his 2019 Big World Tour — featuring special guests — that will be unveiled shortly. Under the patronage of His Royal Highness Sheikh Hamad Bin Isa Al Khalifa, the King of Bahrain, The Kingdom of Bahrain was specifically chosen by RedOne, having a strong passion for genuine Arabic and Muslim culture and heritage with a mix of modern and cutting-edge facilities.


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”